If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Eloralintide
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
Is eloralintide a selective amylin receptor agonist?
Eloralintide acts as a selective amlin receptor agonist, It is currently in phase 2 studied for the treatment of obesity.
Selective Amylin Agonist
Eloralintide has selectivity for amylin-1 receptors (AMY1R) over amylin-3 receptors (AMY3R) or calcitonin receptors (CTR) in human assays (see In Vitro Receptor Binding Affinity – Fold Difference in Ki).1
Eloralintide exhibits approximately 12-fold greater potency for AMY1R and approximately 11-fold greater potency for AMY3R compared with CTR in humans.1
Peptide |
AMY1R vs CTR |
AMY-3R vs CTR |
AMY1R vs AMY3R |
In human receptors |
|||
Eloralintide (human receptor) |
8.1 |
1.1 |
7.5 |
Cagrilintide (human receptor) |
2.5 |
1.6 |
1.6 |
In rat receptors |
|||
Eloralintide |
109.4 |
32.7 |
3.3 |
Cagrilintide |
1.2 |
2.8 |
0.4 |
Abbreviations: AMY1R = amylin 1 receptor; AMY3R = human amylin 3 receptor; CTR = human calcitonin receptor; Ki = inhibition constant.
Rat models suggest that selectively targeting AMY1R or AMY3R compared with CTR, may
- reduce food intake
- improve body weight loss, and
- improve gastrointestinal tolerability.1
Further research is needed to determine the functional significance of selectivity in humans.
References
1Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. 2025:102;102271. https://doi.org/10.1016/j.molmet.2025.102271
Date of Last Review: November 03, 2025